Back to News
Market Impact: 0.2
Charles River, Labcorp, and FDA Collaborate to Validate New Preclinical Methods for Abuse Potential Assessment
Source: Business Wire
Healthcare & BiotechTechnology & Innovation
Charles River announced a collaboration with the U.S. FDA and Labcorp to develop screening tools that quantify and rank the abuse potential of new drugs. The announcement provides no timeline, financial terms, or expected market impact.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.20
Ticker Sentiment
CRL0.60
LH0.30
More News
- Asia stocks fall as AI rout batters S.Korea; Japan spooked by strong CPI
- SK Hynix shares slide after chipmaker scraps Solidigm IPO plans
- Why is SK Hynix stock sliding today?
- Apple’s iPhone Duo Hits Stores in Face of Short Supply and High Demand
- Gold Holds Near Three-Month Low as AI Jitters Fuel Volatility
- OpenAI nears up to $30 billion funding round at $1.25 trillion valuation led by UAE investors
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- How to Evaluate AI Report Writers for Financial Analysis
- Weekly Update: Sector Analysis, Improvements on Research Data, and Performance Enhancements